 | |
| Clinical data | |
|---|---|
| Trade names | Lorabid |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601206 |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 25% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H16ClN3O4 |
| Molar mass | 349.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Loracarbef is anantibiotic.[1] It is acarbacephem, but it is sometimes grouped together with the second-generationcephalosporin antibiotics. Loracarbef is a synthetic "carba"analog ofcefaclor, and is more stable.
Loracarbef received FDA approval in 1991 and it was marketed under the trade nameLorabid. Its use was discontinued in 2006.[citation needed]
Loracarbef was used to treat infections of the lungs, maxillary sinuses, throat, skin, and urinary tract.[2]
Loracarbef had broad spectrum effectiveness against both gram-negative and gram-positive bacteria, including those precipitating infections of the respiratory tract, sinuses, tonsils, skin, urinary tract, and kidneys. It was of specific use in those infections caused byE. coli,S. pyogenes,S. aureus,S. saprophyticus,S. pneumoniae,H. influenzae andM. catarrhalis.[3]
Diarrhea is the most common adverse effect with loracarbef. Side effects are more frequently seen with children under the age of twelve.[citation needed]
